Clinical trials: Thrombin
Differences in Laboratory Coagulation Parameters
Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study
Rivaroxaban represent a new class of anticoagulation agents. As an oral direct factor Xa inhibitor it has been effective in preventing venous thromboembolism in patients undergoing elective orthopaedic surgery.
- Trial name
- NCT00986635
- Where
- Germany
- Volunteers
- 100 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Factor V Leiden, Prothrombin G20210A
Engagement Study for Participants With Factor V Leiden and Prothrombin G20210A Mutations
This study will enrol individuals who have, or may have, Factor V Leiden or Prothrombin G20210A mutations, which are genetic changes linked to an increased risk of blood clots.
- Trial name
- NCT07584265
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Richmond Research Institute
ATIII Deficiency
Anti-thrombin III (ATIII) vs Placebo in Children (<7mo) Undergoing Open Congenital Cardiac Surgery
The purpose of this study is to test whether the administration of ATIII during the intra-operative period results in improved anticoagulation for cardiopulmonary bypass (CPB) and an attenuation of the activation of the…
- Trial name
- NCT02103114
- Testing
- Anti-thrombin III
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Duke University
Bleeding
A Two-part Study in Edoxaban-treated Healthy Subjects to Establish a Punch Biopsy Bleeding Model and to Evaluate the Effect of a 4-factor Prothrombin Complex Concentrate on Anticoagulation
This Phase 1 study consists of 2 parts. Part 1 will be an open-label, randomized, 2 treatment, 2-way crossover study. Part 2 will be a double-blind (Sponsor unblinded), randomized, placebo controlled, sequential descending…
- Trial name
- NCT02047565
- Testing
- 60mg edoxaban, 180mg edoxaban, 50 IU/kg Beriplex P/N
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo
Bleeding Disorder
Bleeding of Unknown Cause: a Swiss Case-control Study
The goal of this prospective cohort is to identified specific biological patterns in patients with a bleeding of unknown cause and to study the specific mechanisms of the bleeding disorder for each subset of patients.
- Trial name
- SWISS-BUC (NCT05713734)
- Testing
- Thrombin generation, Fibrinolysis, Fibrin clot structure
- Where
- 7 sites in Switzerland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Geneva
Hereditary Factor VIII Deficiency Disease With Inhibitor
A Comparison Study of Bypassing Agent Therapy With and Without Tranexamic Acid in Haemophilia A Patients With Inhibitor
Activated prothrombin complex concentrate (aPCC) and recombinant activated factor VII (rFVIIa) are the only two drugs that are available to treat bleeds in haemophilia A patients with high titer inhibitors.
- Trial name
- BPATXAS (NCT01800435)
- Testing
- aPCC, aPCC + TXA, rFVIIa, rFVIIa + TXA
- Where
- Norway
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation
Evaluation of a Preventive Therapeutic Strategy for Postpartum Venous Thromboembolism in Women With Genetic Risk Factor
Background : pregnancy and postpartum period are times of increased risk for deep vein thrombosis (DVT). The incidence of venous thromboembolic disease (VTE) during pregnancy is estimated at 1-2 per 1,000, and this risk increases…
- Conditions
- Factor V Leiden Heterozygous Mutation, Factor II Heterozygous Mutation, Pregnancy, Postpartum
- Trial name
- POSTPART AS5-2 (NCT07342127)
- Testing
- Retrospective collection of health data, Phone call to every participant
- Where
- 2 sites in France
- Volunteers
- 86 people
- Sponsor
- Hospices Civils de Lyon
Effect of Different Reagents., Oral Anticoagulant Therapy
Differences in Coagulation Test Kits
The aim of this study is to assess the effect of Innovin® reagent on laboratory results when compared with the Thromborel® S.
- Trial name
- NCT01109667
- Where
- Turkey (Türkiye)
- Volunteers
- 350 people
- Sponsor
- Yuksek Ihtisas Hospital
Thrombosis
Study Of Angiomax In Infants Under Six Months With Thrombosis
The goals of this study are: 1. To assess the safety of bivalirudin in infants under six months with arterial or venous thrombosis; 2.
- Trial name
- NCT00043277
- Testing
- Angiomax (bivalirudin)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The Medicines Company
Hemophilia
Tissue Factor Pathway Inhibitor (TFPI) and Haemorrhagic Manifestations in Haemophilia A and B Patients
Haemophilia is a rare and serious congenital defect of blood coagulation due to a genetic mutation on a sexual chromosome. It affects quasi-essentially the men and it is responsible for bleeding.
- Trial name
- NCT02540187
- Testing
- blood specimen
- Where
- 7 sites in France
- Volunteers
- 164 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Healthy Volunteers
Normal Values of Parameters of Thrombin Generation in Function of Different Tissue Factor Concentrations
The thrombin generation assay (TGA) is a good tool for measuring clot formation in plasma.TGA using Calibrated Automated Thrombography method, enables the quantification of thrombin concentrations in platelet-rich plasma (PRP)…
- Trial name
- NUAGE (NCT04842084)
- Testing
- Blood samples
- Where
- France
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Haemodialysis
Evaluation of the Validity of the Prothrombin Time Internation Normalised Ratio (PT/INR) Measured at the point-of Care on the Arterial Bloodline of Haemodialysis Extracorporeal Blood Flow
The purpose of this study is to evaluate the INR value of hemodialyzed patient coagulation state (prothrombin time) measured inside the therapeutical zone and thanks to a portable monitor.
- Trial name
- COAGHEMO (NCT02902848)
- Where
- France
- Volunteers
- 30 people
- Sponsor
- University Hospital, Brest
Oral Anticoagulation
User Performance Evaluation of the INRatio® Prothrombin Time (PT) Monitoring System With a New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity
This multi-center study is designed to evaluate the ability of intended lay users (patients on oral anticoagulation therapy, OAT, or their caregivers) to 1) operate the INRatio Prothrombin Time (PT) Monitoring System utilizing…
- Trial name
- ECLIPSE-02 (NCT01036646)
- Where
- 4 sites in United States
- Volunteers
- 183 people
- Sponsor
- Abbott RDx Cardiometabolic
HCC, Cirrhosis, Liver
Use of Blood Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma (HCC)
The objective of this observational study is to evaluate the clinical utility of the combined assay of 3 biomarkers: α-FP, α-FP-L3 and DCP (simultaneously measured by µTASWakoTM i30 automated in vitro diagnostic system) in…
- Conditions
- HCC, Cirrhosis, Liver, NAFLD, HBV
- Trial name
- GALAD (NCT05781568)
- Testing
- Biomarker dosage
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Sepsis, Blood Coagulation Disorders
Analysis of the Coagulopathy Developed by COVID-19 Infected Patients
Increased D-dimers at admission of COVID-19 infected patients entering hospital due to a severe disease is a risk factor for death.
- Conditions
- Sepsis, Blood Coagulation Disorders, Thrombin, Disseminated Intravascular Coagulation
- Trial name
- COVID-TGT (NCT04356950)
- Testing
- Thrombin generation test assay, Fibrin generation markers assays
- Where
- 4 sites in France
- Volunteers
- 175 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cardiovascular, Neurologic (Spine), and General Surgery
A Study to Compare Human Thrombin Against Bovine Thrombin in Its Ability to Stop Bleeding After Surgery
The purpose of this study is to see if Human Thrombin is as effective as Bovine Thrombin in stopping surgical bleeding within 10 minutes of application.
- Trial name
- NCT00196534
- Testing
- Human Thrombin, Bovine Thrombin
- Where
- 17 sites in United States
- Volunteers
- 304 people
- Sponsor
- Ethicon, Inc.
Spinal Tumor, Spinal Injury
Study of Collagen-Based Thrombin Hemostat for the Control of Bleeding in Spinal Surgery
This clinical trial evaluates the effectiveness and safety of a collagen-based hemostatic agent containing thrombin in patients undergoing spinal surgery.
- Conditions
- Spinal Tumor, Spinal Injury, Hemostasis, Spinal Stenosis
- Trial name
- NCT07354178
- Testing
- CollaStat®, Floseal®
- Where
- 3 sites in South Korea
- Volunteers
- 130 people
- Sponsor
- DALIM TISSEN Co., Ltd.
Hemoptysis
A Clinical Study to Evaluate the Efficacy and Safety of Hemocoagulase Injection
This is a multi-centre, randomised, double blind, placebo controlled clinical study which is designed to evaluate the efficacy and safety of hemocoagulase in the treatment of moderate to severe hemoptysis.
- Trial name
- NCT03270735
- Testing
- Snake venom thrombin (Treatment)
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Lee's Pharmaceutical Limited
Pulmonary Embolism, Atrial Fibrillation
Evaluation of the Accuracy and Precision of the INRatio® Prothrombin Time (PT) Monitoring System With New INRatio Test Strip Designed for Low Sample Volume and Heparin Insensitivity
This is a multi-center study designed to evaluate the accuracy and precision of the INRatio® Prothrombin Time (PT) Monitoring System, utilizing the INRatio test strip newly designed for low sample volume and heparin…
- Conditions
- Pulmonary Embolism, Atrial Fibrillation, Deep Vein Thrombosis
- Trial name
- ECLIPSE-01 (NCT01037270)
- Where
- 4 sites in United States
- Volunteers
- 271 people, healthy volunteers welcome
- Sponsor
- Abbott RDx Cardiometabolic
Hepato Cellular Carcinoma (HCC), Portal Vein Tumour Thrombosis
PIVKA-II for Predicting Portal Vein Thrombosis in Hepatocellular Carcinoma
The goal of this cross-sectional observational study is to evaluate the relation between Prothrombin induced by vitamin K absence II (PIVKA-II) and the presence of portal vein tumor thrombosis (PVTT) in hepatocellular carcinoma…
- Trial name
- NCT06960954
- Testing
- Prothrombin induced by vitamin K absence II (PIVKA-II)
- Where
- Egypt
- Volunteers
- 116 people
- Sponsor
- Tanta University